Hara Takeshi, Nagata Mariko, Yamashita Yasunobu, Fujimoto Kenji, Muraki Yosuke, Yasuda Yuko, Kurahashi Toshinori
Dept. of Gastroenterology, Wakayama Rosai Hospital.
Gan To Kagaku Ryoho. 2008 Jul;35(7):1233-7.
Combination chemotherapy with S-1 and gemcitabine(GEM)was given to patients with advanced pancreatic cancer and favorable results were obtained. These patients were 77-(Stage IVa), 68-(Stage IVb), and 64-year-old males (Stage IVb). They were administered S-1 at a dose of 80-100 mg/day for 2 weeks and GEM at a dose of 1,000-1,200 mg/body on days 8 and 15 followed by a 2-week recovery period. One course consisted of a 2-week treatment period and a recovery period; this course was repeated in all of these patients. The 3 types of patients have survived for a year and five months, a year and three months, and nine months, respectively, after diagnosis. In the first patient, who was in Stage IVa, the primary cancer has been maintained in a reduced state without metastasis. In the other two patients, who were in Stage IVb, the primary cancer and hepatic metastatic lesions have been reduced remarkably. Quality of life is good in all the patients. Combination therapy with S-1 and GEM can be provided for a long-term treatment with few adverse reactions on an outpatient basis. Based on the changes in tumor markers, we observed that the inhibitory effects of this combination chemotherapy are immediate and persistent with long-term treatment. Therefore, we expect S-1/GEM combination therapy to be the chemotherapy of choice for advanced pancreatic cancer.
对晚期胰腺癌患者采用S-1与吉西他滨（GEM）联合化疗，取得了良好效果。这些患者分别为77岁男性（IVa期）、68岁男性（IVb期）和64岁男性（IVb期）。他们接受S-1治疗，剂量为80 - 100毫克/天，持续2周，在第8天和第15天接受GEM治疗，剂量为1000 - 1200毫克/体，随后有2周的恢复期。一个疗程包括2周的治疗期和1周的恢复期；所有这些患者均重复该疗程。这3例患者在诊断后分别存活了1年零5个月、1年零3个月和9个月。在IVa期的首例患者中，原发性癌症保持缩小状态且无转移。在另外两例IVb期患者中，原发性癌症和肝转移病灶明显缩小。所有患者的生活质量良好。S-1与GEM联合治疗可以在门诊长期进行，不良反应较少。基于肿瘤标志物的变化，我们观察到这种联合化疗的抑制作用迅速且持久，可长期维持。因此，我们期望S-1/GEM联合治疗成为晚期胰腺癌的首选化疗方案。
